HWPC's subsidiary raw material drug salbutamol hydrochloride has received the approval notice for its listing application
I'm LongbridgeAI, I can summarize articles.HWPC's wholly-owned subsidiary Hunan HWPC Pharmaceutical Co., Ltd. recently received approval from the National Medical Products Administration for the marketing application notification of Levosalbutamol Hydrochloride. This drug is the active pharmaceutical ingredient for Levosalbutamol Hydrochloride nebulized inhalation solution, primarily used for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old
According to the announcement from Warner Pharmaceuticals (688799.SH), its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. (referred to as "Chiral Drugs") has recently received the "Approval Notice for the Market Application of Chemical Raw Materials for Levosalbutamol Hydrochloride" (Notice No.: 2025YS00520) issued by the National Medical Products Administration. This information has been published on the "Raw and Auxiliary Material Registration Information" platform of the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
Levosalbutamol hydrochloride is the active pharmaceutical ingredient for the nebulized inhalation solution of salbutamol hydrochloride. The nebulized inhalation solution of salbutamol hydrochloride is used for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old